Profile

Cover photo
NapCFA
Works at BioNap Consulting, Inc.
Attended Wake Forest University
Lived in Charlotte, NC
56 followers|2,120,860 views
AboutPostsPhotos

Stream

NapCFA

Shared publicly  - 
 
Time To Go Long Brainstorm Cell Therapeutics?
BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is biopharmaceutical company developing adult stem cell-based therapies for a variety of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson’s disea...
BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is biopharmaceutical company developing adult stem cell-based therapies for a variety of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), multiple scler...
1

NapCFA

Shared publicly  - 
 
JPM Meeting Notes - Matinas Biopharma (MTNB)
In my pervious commentary on Matinas Biopharma (MTNB) called the company one of my best ideas for 2017. That certainly did not change after my meeting with management. My conversations with the company focused on the ongoing warrant exchange and timelines f...
1

NapCFA

Shared publicly  - 
 
JPM Meeting Notes - BriaCell Therapeutics (BCT.V)
BriaCell Therapeutics (BCT.V) anticipates getting the 24-patient Phase 2a study up and enrolling patients by the end of the quarter. That’s good news because even though it’s a small and early-stage program, it’s a big potential value driver on both the mar...
1

NapCFA

Shared publicly  - 
 
JPM Meeting Notes - MabVax Therapeutics (MBVX)
MabVax Therapeutics (MBVX) is another company I had a very opportunistic meeting with because they announced that morning the  IND for MVT-1075  had been filed. If all goes smoothly, we should see MVT-1075 in the clinic in the second quarter 2017. Now we al...
1

NapCFA

Shared publicly  - 
 
JPM Meeting Notes - Can-Fite Biopharma (CANF)
I picked a good day to meet with Can-Fite Biopharma (CANF) because that morning the company announced  IRB approval  from Hadassah Medical Center and Rabin Medical Center, two leading medical institutions in Israel, to commence patient enrollment in a Phase...
1

NapCFA

Shared publicly  - 
 
JPM Meeting Notes - HedgePath Pharmaceuticals (HPPI)
HedgePath Pharmaceuticals (HPPI) is another name I’m very excited about for 2017. The company’s Phase 2b trial with SUBA-Cap (itraconazole) is continuing to enroll patients. Target enrollment is 40 patients and it sounds like the company will get to that nu...
1

NapCFA

Shared publicly  - 
 
JPM Meeting Notes - Immune Pharmaceuticals (IMNP)
It’s hard to imagine a 21¢ stock with more going on than Immune Pharmaceuticals (IMNP) ! The company is really trying in my opinion. There have clearly been past struggles, but I have no issues with the current strategy. That said, I see and hear confusion ...
1

NapCFA

Shared publicly  - 
 
JPM Meeting Notes - InVivo Therapeutics (NVIV)
My meeting with InVivo Therapeutics (NVIV) was rather boring. We talked about the weather and Boston sports teams – not much to report. Just kidding! Obviously, enrollment was a primary topic of discussion. Management continues to believe that the pace will...
1

NapCFA

Shared publicly  - 
 
JPM Meeting Notes - Actinium Pharmaceuticals (ATNM)
During my meeting with Actinium Pharmaceuticals (ATNM) we delved deeper into the topic I covered via a  separate article  last week – the clinical hold placed on Seattle Genetics SGN-CD33A. I can go into a lot more detail if necessary, but I think if invest...
1

NapCFA

Shared publicly  - 
 
JPM Meeting Notes - Valeritas Holdings (VLRX)
If you guys follow me on Twitter, you might have seen  a picture  that I tweeted of Valeritas Holdings (VLRX) V-Go® device. This is a really cool single use, disposable, wearable, daily insulin device for type-2 diabetics that required both basal (backgroun...
1

NapCFA

Shared publicly  - 
 
JPM Meeting Notes - Matinas Biopharma (MTNB)
In my pervious commentary on Matinas Biopharma (MTNB) called the company one of my best ideas for 2017. That certainly did not change after my meeting with management. My conversations with the company focused on the ongoing warrant exchange and timelines f...
1

NapCFA

Shared publicly  - 
 
JPM Meeting Notes - VistaGen Therapeutics (VTGN)
I think VistaGen Therapeutics' (VTGN) AV-101 is one of the more interesting small-cap biopharma assets in mid-stage development. I’ve written in the past that I think AV-101 has  blockbuster sales  potential. The drug is currently in a Phase 2a study at the...
1
Story
Tagline
Give me a bottle of anything, and a glazed donut...to go!
Introduction
Women interested in exchanging naked photos with me... you go first. I promise I'll follow-up.
Bragging rights
I shot a 73, +1 over par last summer!
Education
  • Wake Forest University
    MBA - Finance, Securities Analysis & Portfolio Management, 1998 - 2000
  • Virginia Polytechnic Institute And State University
    BS - Biochemistry & Molecular Biology, 1992 - 1996
Basic Information
Gender
Male
Looking for
Networking
Relationship
Married
Work
Occupation
Pharma / Biotech Stock Analyst
Skills
Mad to Crazy-Mad
Employment
  • BioNap Consulting, Inc.
    Owner, 2015 - present
  • Zacks SCR
    Managing Director, 2002 - 2015
  • Eastover Capital
    Analyst, 1998 - 2002
  • Techlab, Inc.
    Bench Scientist, 1995 - 1998
Places
Map of the places this user has livedMap of the places this user has livedMap of the places this user has lived
Previously
Charlotte, NC
Links
YouTube
Contributor to